ArticleAPL bioengineering2025
Survivin modulates stiffness-induced vascular smooth muscle cell motility.
Article in APL bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Engineering a Matrix-Preserving Vascular dECM Platform with Tunable Stiffness forbioRxiv : the preprint server for biology · 2026Article
- Mechanomedicine: Translating mechanical forces into therapeutic strategies.APL bioengineering · 2025Article
- Three-dimensional spheroid models for cardiovascular biology and pathology.Mechanobiology in medicine · 2025Review
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
Arterial stiffness is a contributor to cardiovascular diseases (CVDs) and is associated with the aberrant migration of vascular smooth muscle cells (VSMCs). However, the mechanisms driving VSMC migration in stiff environments remain unclear. We recently demonstrated that survivin is upregulated in mouse and human VSMCs cultured on stiff hydrogels, where it modulates stiffness-mediated cell proliferation. However, its role in stiffness-dependent VSMC migration remains unknown. To assess its impact on migration, we performed time-lapse microscopy on VSMCs seeded on fibronectin-coated soft and stiff hydrogels, mimicking the physiological stiffness of normal and diseased arteries. We observed that VSMC motility increased under stiff conditions, while pharmacologic or siRNA-mediated inhibition of survivin reduced stiffness-stimulated migration to rates similar to those observed under soft conditions. Further investigation revealed that cells on stiff hydrogels exhibited greater directional movement and robust lamellipodial protrusion compared to those on soft hydrogels. Interestingly, survivin-inhibited cells on stiff hydrogels showed reduced directional persistence and lamellipodial protrusion. We also found that survivin overexpression modestly increased cell motility and partially rescued the lack of directional persistence compared to green fluorescent protein (GFP)-expressing VSMCs on soft hydrogels. Mechanistically, stiffness- and survivin-dependent cell migration involves focal adhesion kinase (FAK) and actin dynamics, as stiffness increases phosphorylated FAK recruitment to focal adhesions and promotes actin organization and stress fiber formation-effects that are disrupted by survivin inhibition. In conclusion, our findings establish that mechanotransduction through a survivin-FAK-actin cascade converts extracellular matrix stiffness into stiffness-sensitive motility, suggesting that targeting this pathway may offer therapeutic strategies for CVD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.